Experienced scientific and commercial leaders.
Peptide science, paired with healthcare transactions and public company experience.
Where molecular science meets deal making.
Dr. J. David Warren
More than two decades of experience in medicinal chemistry, peptide science and translational research. Adjunct Associate Professor of Research in Biochemistry and Biophysics at Weill Cornell Medicine and former Director of the Milstein Chemistry Core Facility.
He has advanced multiple compounds into preclinical development, holds 17 issued United States and international patents, and has authored or coauthored more than 53 peer reviewed publications and book chapters.
His published work includes foundational mechanistic research on SS 31, now known as elamipretide. Elamipretide was later developed by others as Forzinity and received FDA accelerated approval in September 2025 for Barth syndrome. That development and approval are separate from Dr. Warren's research contribution. Adaptogenics did not develop and does not own elamipretide.
Published mechanistic research on SS 31 (elamipretide). Not an Adaptogenics asset.
Antoun Nabhan
Healthcare executive and investor with close to two decades of experience. Led more than US$2 billion in buy side healthcare transactions associated with four product approvals: Kyprolis, Stivarga, Quinsair and Somryst.
Former Chief Financial Officer of Establishment Labs and Vice President of Corporate Development at Soleno Therapeutics, with leadership roles in both companies' Nasdaq IPO processes. Held transactional roles at Onyx Pharmaceuticals before its acquisition by Amgen. Cofounded three pharmaceutical companies, including Convivia and Incellico, which were acquired.
J.D., Harvard Law School. A.B., University of Chicago, Phi Beta Kappa.
Prior transactions and approvals were achieved elsewhere and are not Adaptogenics assets.
Done it before, from founding to public markets.
pharmaceutical companies cofounded, including Convivia and Incellico, both acquired
issued patents, with 53+ publications and book chapters, held by Dr. Warren
in buy side healthcare transactions led, associated with four product approvals
Nasdaq IPO processes with leadership roles, at Establishment Labs and Soleno Therapeutics
Achieved by our leaders at other organizations. These are not Adaptogenics results.
Scientific depth to choose and shape molecules. Commercial experience to build value around them.
Follow the build.
Company overview, official releases and records, as they are verified and issued.